ChinaAMC Hang Seng Biotech ETF (03069.HK) Down 2.23% as Akeso Slides 22.6%

ChinaAMC Hang Seng Biotech ETF (03069.HK) fell 2.23% to HK$14.490 as Akeso slid over 22% on an FDA complete response letter for ivonescimab.
Key Highlights:
  • NAV per unit was HK$14.8199 with AUM of HK$3.826 billion (November 13); the price trades about 2.23% below NAV and the management fee is 0.5% a year.
  • Akeso touched HK$56.1 intraday, a low since February 2025, and traded at HK$63.7 by 15:21, down 22.60%, on turnover above HK$2.7 billion.
  • Jefferies notes the rejected indication has roughly 8,000 eligible patients annually and unadjusted peak sales of about US$400 million, versus US$17.2 billion for ivonescimab overall.

NewTimeSpace News: As of 15:35 on November 16, ChinaAMC Hang Seng Biotech ETF (03069.HK) fell 2.23% to a latest price of HK$14.490. The ETF has so far traded 5.2381 million units today, with turnover of HK$75.628 million and an average price of HK$14.438; its turnover rate is 2.029%. It has fallen 2.23% week to date. The net asset value per unit is HK$14.8199, and assets under management stand at HK$3.826 billion. (Note: NAV and AUM are as of November 13; the week-to-date change is based on the close of HK$14.820 on November 13, the last trading day of the prior week, so it matches the one-day change; the price trades at a discount of about 2.23% to NAV.)

Hong Kong innovative drug shares retreated sharply on November 16. Akeso opened at HK$70, about 15% below the previous close of HK$82.3, and fell as low as HK$56.1 intraday, nearly 32% down and a low since February 2025; at 15:21 it stood at HK$63.7, down 22.60%, with turnover exceeding HK$2.7 billion. The trigger came from partner Summit Therapeutics, which disclosed on November 15 that the US Food and Drug Administration had issued a complete response letter for the biologics licence application for ivonescimab (AK112) plus platinum chemotherapy in EGFR-TKI-pretreated non-squamous non-small cell lung cancer; the application was not approved. The FDA said that although the HARMONi study met its progression-free survival primary endpoint, overall survival did not reach statistical significance and the efficacy evidence was insufficient. Akeso chair Yu Xia said at a November 15 conference call that this was the most disappointing moment in the company's 14-year history, while stressing that the decision applied only to a specific indication and would not affect other global trials, with share buybacks under consideration. Other sector names fell less: Innovent Biologics lost 1.00%, BeiGene 0.48%, Sino Biopharmaceutical 1.62% and WuXi AppTec 1.04%, while the Hang Seng Index rose 0.43% and the Hang Seng TECH Index fell 0.29%.

ChinaAMC Hang Seng Biotech ETF (03069.HK) is a passive ETF under ChinaAMC (Hong Kong) that closely tracks the Hang Seng Biotech Index. Compiled by Hang Seng Indexes on a net total return basis, the index reflects the performance of the 30 largest Stock Connect-eligible biotech companies listed in Hong Kong, including pre-revenue companies listed under Chapter 18A. Constituents span biotechnology, pharmaceuticals, pharmaceutical distribution, pharmaceutical and biotech contract services, and medical equipment and supplies, weighted by free-float market capitalisation with a 10% cap on any single constituent. The product listed on March 18, 2021, with a management fee of 0.5% per year.

Jefferies believes the delay in bringing ivonescimab to the US market leaves the investment thesis intact, because second-line EGFR-mutant non-small cell lung cancer represents only a small part of the drug's global potential. Chinese trial sites and the Guangzhou production facility have passed inspections, indicating the issue lies in the lack of statistically significant overall survival rather than data quality, manufacturing or new safety concerns. The brokerage estimates about 8,000 eligible patients a year in this indication and unadjusted peak sales of roughly US$400 million, a small share of ivonescimab's unadjusted peak sales of US$17.2 billion; HARMONi-6 and HARMONi-2 subsequently produced statistically significant overall survival hazard ratios of 0.66 and 0.73 against tislelizumab and pembrolizumab respectively.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.